{"prompt": "['Protocol', 'ALXN1210-MG-306 Amendment 2', '8.1.3.', 'Myasthenia Gravis Activities of Daily Living Profile', 'The MG-ADL is an 8-point questionnaire that focuses on relevant symptoms and functional', 'performance of ADL in patients with MG (Section 10.6 [Appendix 6]). The 8 items of the', 'MG-ADL questionnaire were derived from symptom-based components of the original 13-item', 'QMG scale to assess disability secondary to ocular (2 items), bulbar (3 items), respiratory', '(1 item), and gross motor or limb (2 items) impairment related to effects from MG. In this', 'functional status instrument, each response is graded 0 (normal) to 3 (most severe). The range of', 'total MG-ADL score is 0 - 24. The recall period for MG-ADL is the preceding 7 days. The MG-', 'ADL profile should be administered by a properly trained evaluator. For consistency, the same', 'evaluator should administer the questionnaire throughout the study.', '8.1.4.', 'Quantitative Myasthenia Gravis Score', 'The QMG scoring system consists of 13 items: ocular (2 items), facial (1 item), bulbar (2 items),', 'gross motor (6 items), axial (1 item), and respiratory (1 item); each graded 0 to 3, with 3 being', 'the most severe (Section 10.7 [Appendix 7]). The range of total QMG score is 0 - 39. The QMG', 'scoring system is considered to be an objective evaluation of therapy for MG and is based on', 'quantitative testing of sentinel muscle groups. The MGFA task force has recommended that the', 'QMG score be used in prospective studies of therapy for MG (Benatar, 2012).', '8.1.5.', 'Myasthenia Gravis Composite Score', 'The MGC is a validated assessment tool for measuring clinical status of patients with MG. The', 'range of total MGC score is 0 - 50. The MGC assesses 10 important functional areas most', 'frequently affected by MG and the scales are weighted for clinical significance that incorporates', 'patient-reported outcomes (Burns, 2010) (Section 10.8 [Appendix 8]).', '8.1.6.', 'Euro Quality of Life 5D-5L', 'The Euro Quality of Life-5L (EQ-5D-5L) (Section 10.9 [Appendix 9]) is a self-assessed,', 'health-related QoL questionnaire. The scale measures QoL on a 5-component scale including', 'mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each level is rated', 'on a scale that describes the degree of problems in that area (ie, I have no problems walking', 'about, slight problems, moderate problems, severe problems, or unable to walk). This tool also', 'has an overall health scale where the rater selects a number between 1 - 100 to describe the', 'condition of their health, 100 being the best imaginable. Convergent validity was demonstrated', 'by a correlation between EQ-5D-5L and the dimensions of World Health Organization 5 Well', 'Being questionnaires, (r = 0.43, p < 0.001) (Janssen, 2013). The EQ-5D-5L approach is reliable,', 'average test-retest reliability using interclass coefficients with mean of 0.78 and 0.73 (Brooks,', '1996; Chaudhury, 2006).', '8.1.7.', 'Revised Myasthenia Gravis Qualify of Life-15 Scale', 'The revised Myasthenia Gravis Qualify of Life 15-item scale (MG-QOL15r) (Section 10.10', '[Appendix 10]) is a health-related QoL evaluative instrument specific to patients with MG. The', \"MG-QOL15r was designed to provide information about patients' perception of impairment and\", 'disability, determine the degree to which disease manifestations are tolerated, and to be', 'Page 54 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', 'administered and interpreted easily (Burns, 2016). The MG-QOL15r will be completed by the', 'patient. Higher scores indicate greater extent of and dissatisfaction with MG-related dysfunction.', '8.1.8.', 'Neurological Quality of Life Fatigue', 'The Neuro-QOL Fatigue is a reliable and validated brief 19-item survey of fatigue, completed by', 'the patient (Cella, 2010). Higher scores indicate greater fatigue and greater impact of MG on', 'activities (Section 10.11 [Appendix 11]).', '8.1.9.', 'Myasthenia Gravis Foundation of America Clinical Classification', 'The MGFA Clinical Classification will be assessed on Day 1 (Section 10.12 [Appendix 12]).', '8.1.10.', 'Myasthenia Gravis Foundation of America Post-Intervention Status', 'The MG clinical state will be assessed using a modified version of the MGFA-PIS', '(Section 10.13 [Appendix 13]). Change in status categories of Improved, Unchanged, or Worse,', 'as well as the minimal manifestation (MM) will be assessed and recorded at the time points', 'indicated in the SoA (Section 1.3) by the Investigator or the same neurologist skilled in the', 'evaluation of patients with MG throughout the study. The subscores of MM, ie, MM-0, MM-1,', 'and MM-3, will not be used in this protocol.', '8.2.', 'Safety Assessments', '8.2.1.', 'Physical Examination', 'A physical examination will include assessments of the following body systems: general', 'appearance; skin; head, ear, eye, nose, throat; neck; lymph node; chest; heart; abdominal cavity;', 'limb; central nervous system; and musculoskeletal. An abbreviated physical examination', 'consists of a body-system relevant examination based upon Investigator judgment and patient', 'symptoms. For consistency, all efforts should be made to have the physical examination', 'performed by the same qualified study staff.', '8.2.2.', 'Vital Signs and Pulse Oximetry', 'Vital signs and pulse oximetry will be measured at every visit and will include assessments of', 'systolic and diastolic BP (mmHg), temperature (\u00b0C or \u00b0F), SO2, and HR (beats per minute). Vital', 'signs will be obtained after the patient has been supine or seated for at least 5 minutes. Ideally,', \"each patient's BP should be measured using the same arm.\", '8.2.3.', 'Electrocardiogram', 'Single 12-lead electrocardiogram (ECG) will be obtained as outlined in the SoA (Section 1.3)', 'using an ECG machine to obtain HR and measures of PR, QRS, QT, and QTc intervals. QT', \"interval will be corrected for heart rate using Fridericia's formula (QTcF). Patients must be\", 'supine for approximately 5 - 10 minutes before ECG collection and remain supine but awake', 'during ECG collection.', 'The Investigator or designee will be responsible for reviewing the ECG to assess whether the', 'ECG is within normal limits and determine the clinical significance of the results. These', 'assessments will be indicated on the eCRF.', 'Page 55 of 109', 'Alexion Confidential']\n\n###\n\n", "completion": "END"}